201 related articles for article (PubMed ID: 25514114)
1. Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.
Gamba S; Camaj P; Heinemann V; Laubender RP; Wang Y; Zhao Y; Stintzing S; Giessen C; Boeck S; Haertl C; Bruns CJ; Modest DP
Anticancer Drugs; 2015 Apr; 26(4):371-8. PubMed ID: 25514114
[TBL] [Abstract][Full Text] [Related]
2. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
[TBL] [Abstract][Full Text] [Related]
4. KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.
Modest DP; Camaj P; Heinemann V; Schwarz B; Jung A; Laubender RP; Gamba S; Haertl C; Stintzing S; Primo S; Bruns CJ
J Cancer Res Clin Oncol; 2013 Jun; 139(6):953-61. PubMed ID: 23455880
[TBL] [Abstract][Full Text] [Related]
5. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
6. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
[TBL] [Abstract][Full Text] [Related]
8. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
9. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model.
Ninomiya T; Takigawa N; Ichihara E; Ochi N; Murakami T; Honda Y; Kubo T; Minami D; Kudo K; Tanimoto M; Kiura K
Mol Cancer Ther; 2013 May; 12(5):589-97. PubMed ID: 23443806
[TBL] [Abstract][Full Text] [Related]
10. Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway.
Deng M; Wang J; Chen Y; Zhang L; Liu D
Anticancer Drugs; 2015 Apr; 26(4):422-7. PubMed ID: 25588160
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines.
Stolze B; Reinhart S; Bulllinger L; Fröhling S; Scholl C
Sci Rep; 2015 Feb; 5():8535. PubMed ID: 25705018
[TBL] [Abstract][Full Text] [Related]
12. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
[TBL] [Abstract][Full Text] [Related]
14. Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells.
Xavier CP; Lima CF; Preto A; Seruca R; Fernandes-Ferreira M; Pereira-Wilson C
Cancer Lett; 2009 Aug; 281(2):162-70. PubMed ID: 19344998
[TBL] [Abstract][Full Text] [Related]
15. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells.
Ariyama H; Qin B; Baba E; Tanaka R; Mitsugi K; Harada M; Nakano S
J Cell Biochem; 2006 Mar; 97(4):724-34. PubMed ID: 16229013
[TBL] [Abstract][Full Text] [Related]
17. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
Han SY; Zhao MB; Zhuang GB; Li PP
Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
[TBL] [Abstract][Full Text] [Related]
18. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations.
Hiramatsu M; Ninomiya H; Inamura K; Nomura K; Takeuchi K; Satoh Y; Okumura S; Nakagawa K; Yamori T; Matsuura M; Morikawa T; Ishikawa Y
Lung Cancer; 2010 Oct; 70(1):94-102. PubMed ID: 20117855
[TBL] [Abstract][Full Text] [Related]
19. A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.
Hickish T; Cassidy J; Propper D; Chau I; Falk S; Ford H; Iveson T; Braun M; Potter V; Macpherson IR; Finnigan H; Lee C; Jones H; Harrison M
Eur J Cancer; 2014 Dec; 50(18):3136-44. PubMed ID: 25441408
[TBL] [Abstract][Full Text] [Related]
20. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
